ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.716,42
-0,12%
S&P 500
5.246,68
0,48%
Dow Jones
39.558,11
0,32%
Euro vs US Dollar
1,08162
0,02%
Bitcoin
61.661,10
0,19%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Entera Bio Ltd (ENTX)

  7. Entera Bio Ltd (ENTX) News

ENTX Entera Bio Ltd

2,49
0,15 (6,41%)
14 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Entera Bio Ltd ENTX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,15 6,41% 2,49 23:22:11
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
2,34 2,02 2,53 2,51 2,34
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
13.5.202413:00GLOBEEntera Bio to Present Phase 1 Data from First-in-Class,..
10.5.202422:14EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10.5.202422:10EDGAR2Form 8-K - Current report
10.5.202422:10GLOBEEntera Bio Reports Q1 2024 Financial Results and Provides..
08.4.202414:30GLOBEEntera Bio Announces Publication of Oral PTH(1-34) Peptide..
26.3.202413:30GLOBEEntera Bio Announces Key Regulatory Milestone for Oral..
20.3.202413:00GLOBEEntera Bio Announces Robust Pharmacokinetic Data for..
08.3.202422:25EDGAR2Form S-8 - Securities to be offered to employees in employee..
08.3.202422:12EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
08.3.202422:10EDGAR2Form 8-K - Current report
08.3.202422:05GLOBEEntera Bio Announces Full Year 2023 Financial Results and..
04.3.202414:30EDGAR2Form 8-K - Current report
04.3.202414:30GLOBEEntera Bio Regains Compliance with Nasdaq Minimum Bid Price..
15.2.202423:10EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
15.2.202406:15EDGAR2Form EFFECT - Notice of Effectiveness
14.2.202412:05EDGAR2Form S-3/A - Registration statement under Securities Act of..
02.2.202422:19EDGAR2Form 8-K - Current report
02.2.202422:17EDGAR2Form S-3 - Registration statement under Securities Act of..
30.1.202414:30GLOBEEntera Bio to Present at the Oppenheimer 34th Annual..
16.1.202414:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.1.202400:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202400:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.1.202422:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.1.202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.1.202422:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.1.202414:00EDGAR2Form 8-K - Current report
27.12.202314:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26.12.202314:00EDGAR2Form 8-K - Current report
26.12.202314:00GLOBEEntera Bio Announces Closing of Private Placement - Extends..
29.11.202314:30GLOBEInterim Results from Ongoing Clinical Study Confirm EB613..
14.11.202313:30GLOBEEntera Bio Reports Q3 2023 Financial Results, Highlights..
09.11.202320:30GLOBEEntera Bio Reports Key Milestone Relating to Oral PTH (1-34)..
16.10.202314:00GLOBEEntera Bio Reports Rapid Pharmacodynamic (PD) Response and..
14.9.202323:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.9.202323:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.9.202322:05EDGAR2Form 8-K - Current report
12.9.202314:30GLOBEEntera Bio Announces Collaboration with OPKO Biologics to..
05.9.202314:00GLOBEEntera Bio to Participate in Upcoming Investor Conferences
24.8.202314:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.8.202314:11EDGAR2Form 3 - Initial statement of beneficial ownership of..
22.8.202315:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.8.202314:30GLOBEEntera Bio to Present Two Abstracts on its First-in-Class,..
15.8.202322:10EDGAR2Form DEF 14A - Other definitive proxy statements
11.8.202322:19EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11.8.202322:16EDGAR2Form 8-K - Current report
11.8.202322:05GLOBEEntera Bio Announces Q2 2023 Financial Results and Corporate..
30.6.202322:06EDGAR2Form 8-K - Current report
07.6.202313:30GLOBEEntera Bio Adds Sanofi Commercial Leader, Haya Taitel to its..

Kürzlich von Ihnen besucht

NASDAQ
ENTX
Entera Bio
TSXV
YUB.P
Yubba Capital
BIT
UC2V7E
Unicredit Bank
BIT
I05216
Banca IMI
LSE
TRE
Ft Tre
BTRX
TUSDUSD
TrueUSD
NYSE
NBR
Nabors Industries
UNSW
$FIREETH
FireStarter
COIN
BTXEUR
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten